Xian-Janssen Promotes Its Paliperidone By Means Of Academic Promotion
This article was originally published in PharmAsia News
Executive Summary
The Chinese Society of Psychiatry, under the Chinese Medical Association, and Xian-Janssen have jointly started a personal and social performance scale training (PSP) course in Guangzhou. The nationwide training program aims to apply scientific psychiatric diagnosis and treatment concepts to clinical practice. Industry observers believe that besides popularizing these concepts, Xian-Janssen is more interested in promoting its schizophrenia drugs. In February this year, the firm introduced in China its extended-release paliperidone tablets, the first FDA-approved anti-psychotic drug that can significantly improve a patient's personal and social functioning, as proven by PSP. Analysts note that pharmaceutical MNCs' advantages in the psychiatry field can be ascribed to their developed academic promotion system. (Click here for more - Chinese Language)
You may also be interested in...
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.